Akebia Therapeutics(AKBA)
搜索文档
Akebia Therapeutics(AKBA) - 2020 Q3 - Quarterly Report
2020-11-06 05:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File Number 001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |-- ...
Akebia Therapeutics(AKBA) - 2020 Q2 - Quarterly Report
2020-08-11 04:14
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File Number 001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-8756903 (S ...
Akebia Therapeutics(AKBA) - 2020 Q1 - Quarterly Report
2020-05-06 04:12
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ | --- | --- | |--------------------------------------------------------------------------------------------|--------------------------- ...
Akebia Therapeutics(AKBA) - 2020 Q1 - Earnings Call Transcript
2020-05-06 01:57
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2020 Earnings Conference Call May 5, 2020 8:30 AM ET Company Participants Kristen Sheppard - SVP, IR John Butler - President and CEO Steven Burke - Chief Medical Officer Jason Amello - CFO Conference Call Participants Allison Bratzel - Piper Sandler Eric Joseph - JPMorgan Difei Yang - Mizuho Securities Bert Hazlett - BTIG Chad Messer - Needham & Company Ed Arce - H.C. Wainwright David Lebowitz - Morgan Stanley Kennen MacKay - RBC Capital Markets Operator Good morni ...
Akebia Therapeutics(AKBA) - 2019 Q4 - Annual Report
2020-03-13 04:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(g) of the Act: None FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-875 ...
Akebia Therapeutics(AKBA) - 2019 Q4 - Earnings Call Transcript
2020-03-11 01:31
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2019 Earnings Conference Call March 10, 2020 9:00 AM ET Company Participants Kristen Sheppard - Vice President, Investor Relations John Butler - President and Chief Executive Officer Jason Amello - Chief Financial Officer Conference Call Participants Chris Raymond - Piper Sandler Eric Joseph - JPMorgan Difei Yang - Mizuho David Lebowitz - Morgan Stanley Ed Arce - H.C. Wainwright Bert Hazlett - BTIG Kennen MacKay - RBC Capital Markets Operator Ladies and gentlemen t ...
Akebia Therapeutics(AKBA) - 2019 Q3 - Quarterly Report
2019-11-13 05:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ | --- | --- | |--------------------------------------------------------------------------------------------|----------------------- ...
Akebia Therapeutics(AKBA) - 2019 Q3 - Earnings Call Transcript
2019-11-13 04:00
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2019 Earnings Conference Call November 12, 2019 9:00 AM ET Company Participants Kristen Sheppard - VP of IR John Butler - President and CEO Jason Amello - CFO Conference Call Participants Chris Raymond - Piper Jaffray Eric Joseph - JP Morgan David Lebowitz - Morgan Stanley Difei Yang - Mizuho Securities Ed Arce - H.C. Wainwright Justin Burns - RBC Capital Markets Operator Ladies and gentlemen, and welcome to the Akebia Therapeutics Third quarter Financial Results a ...
Akebia Therapeutics(AKBA) - 2019 Q2 - Earnings Call Transcript
2019-08-10 21:05
Akebia Therapeutics Inc. (NASDAQ:AKBA) Q2 2019 Results Conference Call August 8, 2019 9:00 AM ET Company Participants Kristen Sheppard - Vice President of Investor Relations John Butler - President and Chief Executive Officer Jason Amello - Chief Financial Officer Conference Call Participants Eric Joseph - JP Morgan Nicole Gabreski - Piper Jaffray David Lebowitz - Morgan Stanley Robert Hazlett - BTIG Alexandre Bouilloux - Mizuho Securties Chad Jason - Needham & Company Ed Arce - H.C. Wainwright Operator Goo ...
Akebia Therapeutics(AKBA) - 2019 Q2 - Quarterly Report
2019-08-09 04:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ | --- | --- | |--------------------------------------------------------------------------------------------|---------------------------- ...